Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study presents a rare instance of Netherton syndrome diagnosed incidentally in siblings of consanguineous parents, initially misdiagnosed as other skin conditions, emphasizing the need for careful evaluation in chronic skin cases to prevent misdiagnosis.

This study found that among patients with stage III and IV androgenic alopecia, 83% of those using topical 5% minoxidil with topical 0.1% finasteride showed improved hair density, suggesting it may reduce the need for long-term oral finasteride.

This study found that pharmacopuncture and needle-embedding therapy may improve hair loss and physical condition in women with androgenetic alopecia, though further clinical research is needed.

In this study, Origanum vulgare extracts showed antioxidant activity and increased insulin-like growth factor-1 expression without causing cytotoxicity in human hair dermal papilla cells.

This study found that combining Ganoderma lucidum extract with microneedle therapy promoted hair growth in a mouse model of alopecia more effectively than microneedle therapy alone.

This review discusses traditional Korean medical treatments for abnormal hair growth (pilosis) and hair removal, highlighting their long history and potential for cosmetic advancement when combined with modern technology; it reports no new clinical results.

This study found that Phellodendri Cortex Ex may reduce prostate tissue damage and inhibit $5{\alpha}$-reductase gene expression in a rat model of benign prostatic hyperplasia, suggesting potential therapeutic benefits.

This study observed that extracts of Biotae Orientalis showed hair growth effects in mice and suggest they may be useful for topical treatment of alopecia areata.

This study suggests that acetone extracts and certain fractions of Drynariae Rhizomas may support hair growth when applied topically in C57BL/6N mice models, indicating potential use for treating alopecia areata.

This study found that the hair of a 16th-century female mummy discovered in Paju was remarkably well-preserved due primarily to a calcium-based surface coating that likely inhibited moisture and microorganism infiltration.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

In this case report, a 16-year-old female with Netherton syndrome, a rare genetic disorder, exhibited symptoms such as skin issues, hair abnormalities, and elevated serum IgE levels. The diagnosis was supported by skin biopsy, and treatment included topical therapies, NB-UVB, and infliximab.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This subject index from the book "Stem Cells in Toxicology and Medicine" offers no new research results.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

The researchers reported that silencing the NtNCED3-2 gene in tobacco reduced ABA content and drought tolerance, inhibited root and leaf development, and decreased photosynthetic ability due to altered isoprenoid metabolism.

This study reports that the new neighborhood face index (NFI) demonstrates a remarkably high correlation with the physiochemical properties of benzenoid hydrocarbons, highlighting its potential as a predictive tool.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

In this study, researchers used NIR-II fluorescence imaging to track the survival and migration of EPI-NCSCs in rat models, finding that these stem cells aided in repairing facial nerve defects when applied via acellular nerve allografts.